NCT04745403View on ClinicalTrials.gov

Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

mRNA HBV/TCR T-cells

"Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW."

Trial Locations (1)

169608

RECRUITING

Singapore General Hospital, Singapore

All Listed Sponsors
lead

Lion TCR Pte. Ltd.

INDUSTRY